Insulin Resistance Among Hepatitis C Infected Children

Evaluation of Insulin Resistance in Hepatitis C Infected Thalassemia Children and Survivors of Childhood Malignancy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07238530

Enrollment

Registered

2025-11-20

Start date

2015-09-30

Completion date

2016-07-01

Last updated

2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This Study is to Assess Occurence of Insulin Resistance Among Hepatits C Infected Children Whether Thalassemic or Survivors of Childhood Malignancy

Brief summary

The goal of this observational study was to study the occurrence of insulin resistance in hepatitis C virus infected children who were either thalassemic or survivors of childhood malignancy and its correlation to the HCV viral load and other metabolic factors. The main question it aims to answer is: 1. Do children infected with Hepatitis C have a higher incidence of Insulin resistance compared to healthy controls of same age and gender? 2. Is Insulin resistance occurence affected by HCV viral load, blood transfusion frequency, or metabolic factors? Researchers will compare hepatitis c infected children who are either thalassemic or survivors of childhood malignant to healthy age and sex matched controls. Participants will be subjected to: * standardized Questionnaires, * physical examination and * laboratory investigations including liver functions (ALT, AST, Alkaline phosphatase), Prothrombin time, serum ferritin level, albumin, fasting glucose, fasting insulin level and Insulin resistance assessment by HOMA IR calculation.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

3 Years to 18 Years

Healthy volunteers

Yes

Inclusion criteria

* hepatitis C virus ribonucleic acid (RNA) positive children, who were following up at the pediatric hematology and oncology clinic

Exclusion criteria

* patients with concurrent active hepatitis B virus infection (positive for hepatitis B surface antigen) or * autoimmune hepatitis, * primary biliary cirrhosis (PBC), * sclerosing cholangitis, * haemochromatosis, * α1-antitrypsin deficiency, * Wilson's disease, * patients with obesity (BMI \> 25), or * Type 2 DM.

Design outcomes

Primary

Measure	Time frame	Description
The primary outcome measure was to study the occurrence of insulin resistance in hepatitis C virus infected children who were either thalassemic or survivors of childhood malignancy	over a period of 6 months	Insulin resistance was assessed by using Homeostasis Model Assessment (HOMA) index

Secondary

Measure	Time frame	Description
Secondary outcome measure was to assess correlation between insulin resistance and HCV viral load and metabolic parameters.	6 months	HCV viral load was measured by HCV RNA level by PCR, and metabolic parameters included liver functions, serum ferritin, fasting glucose and fasting insulin

Countries

Egypt

Outcome results